ACRS

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Wayne, Pennsylvania. The company went public in October 2015 and focuses on developing novel drug candidates for immune-inflammatory diseases. Aclaris operates through two business segments: a Therapeutics division that develops innovative therapies for significant unmet medical needs in immuno-inflammatory conditions, and a Contract Research segment that provides laboratory services to generate additional revenue while advancing its core drug development mission.